Maximizing Outcomes in Respiratory Tract Infections in the Age of ResistanceNICOLAU, David P.Pharmacotherapy. 2002, Vol 22, Num 1, issn 0277-0008, 34 p., 2Conference Proceedings

Optimizing outcomes with antimicrobial therapy through pharmacodynamic profilingNICOLAU, David P.Journal of infection and chemotherapy. 2003, Vol 9, Num 4, pp 292-296, issn 1341-321X, 5 p.Article

Development of an HPLC method for the determination of doripenem in human and mouse serumSUTHERLAND, Christina; NICOLAU, David P.Journal of chromatography. B. 2007, Vol 853, Num 1-2, pp 123-126, issn 1570-0232, 4 p.Article

Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungsCRANDON, Jared L; KIM, Aryun; NICOLAU, David P et al.Journal of antimicrobial chemotherapy (Print). 2009, Vol 64, Num 4, pp 837-839, issn 0305-7453, 3 p.Article

Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniaeNICOLAU, David P; AMBROSE, Paul G.The American journal of medicine. 2001, Vol 111, Num 9A, pp 13S-18S, issn 0002-9343Article

Tigecycline Displays In Vivo Bactericidal Activity against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae after 72-Hour Exposure PeriodTESSIER, Pamela R; NICOLAU, David P.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 1, pp 640-642, issn 0066-4804, 3 p.Article

Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia modelKOOMANACHAI, Pornpan; KIM, Aryun; NICOLAU, David P et al.Journal of antimicrobial chemotherapy (Print). 2009, Vol 63, Num 5, pp 982-987, issn 0305-7453, 6 p.Article

Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniaeDERYKE, C. Andrew; XIAOLI DU; NICOLAU, David P et al.Journal of antimicrobial chemotherapy (Print). 2006, Vol 58, Num 3, pp 601-609, issn 0305-7453, 9 p.Article

Production and resolution of cantharidin-induced inflammatory blistersMAGLIO, Dana; NIGHTINGALE, Charles H; NICOLAU, David P et al.International journal of antimicrobial agents. 2003, Vol 22, Num 1, pp 77-80, issn 0924-8579, 4 p.Article

Optimizing economic outcomes in acute exacerbations of chronic bronchitisDESTACHE, Christopher J.Pharmacotherapy. 2002, Vol 22, Num 1, pp 12-17, issn 0277-0008, 2Conference Paper

The emerging role of atypical pathogens in community-acquired pneumoniaGLEASON, Patrick P.Pharmacotherapy. 2002, Vol 22, Num 1, pp 2-11, issn 0277-0008, 2Conference Paper

In Vitro Activity of Novel Gyrase Inhibitors against a Highly Resistant Population of Pseudomonas aeruginosaTESSIER, Pamela R; NICOLAU, David P.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 6, pp 2887-2889, issn 0066-4804, 3 p.Article

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniaeBULIK, Catharine C; NICOLAU, David P.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 6, pp 3002-3004, issn 0066-4804, 3 p.Article

In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug ResistanceBULIK, Catharine C; CHRISTENSEN, Henry; NICOLAU, David P et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 1, pp 557-559, issn 0066-4804, 3 p.Article

Deep and organ/space infections in patients undergoing elective colorectal surgery: incidence and impact on hospital length of stay and costsEAGYE, Kathryn J; NICOLAU, David P.The American journal of surgery. 2009, Vol 198, Num 3, pp 359-367, issn 0002-9610, 9 p.Article

Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections : A report from the OPTAMA programMAGLIO, Dana; KUTI, Joseph L; NICOLAU, David P et al.Clinical therapeutics. 2005, Vol 27, Num 7, pp 1032-1042, issn 0149-2918, 11 p.Article

Pleconaril, a novel antipicornaviral agentFLOREA, Naomi R; MAGLIO, Dana; NICOLAU, David P et al.Pharmacotherapy. 2003, Vol 23, Num 3, pp 339-348, issn 0277-0008, 10 p.Article

When Pharmacodynamics Trump Costs: An Antimicrobial Stewardship Program's Approach to Selecting Optimal Antimicrobial Agents : ANTIMICROBIAL STEWARDSHIP: IMPACT AND CHALLENGESGOFF, Debra A; NICOLAU, David P.Clinical therapeutics. 2013, Vol 35, Num 6, pp 766-771, issn 0149-2918, 6 p.Article

Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenemEAGYE, Kathryn J; NICOLAU, David P.Journal of antimicrobial chemotherapy (Print). 2011, Vol 66, Num 6, pp 1392-1395, issn 0305-7453, 4 p.Article

Is all free time above the minimum inhibitory concentration the same : implications for β-lactam in vivo modellingDERYKE, C. Andrew; NICOLAU, David P.International journal of antimicrobial agents. 2007, Vol 29, Num 3, pp 341-343, issn 0924-8579, 3 p.Article

Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainmentKUTI, Joseph L; NICOLAU, David P.Chemotherapy (Basel). 2005, Vol 51, Num 4, pp 211-216, issn 0009-3157, 6 p.Article

Making the most of surveillance studies : Summary of the OPTAMA ProgramKUTI, Joseph L; NICOLAU, David P.Diagnostic microbiology and infectious disease. 2005, Vol 53, Num 4, pp 281-287, issn 0732-8893, 7 p.Article

Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosingDAWEI XUAN; NICOLAU, David P; NIGHTINGALE, Charles H et al.International journal of antimicrobial agents. 2004, Vol 23, Num 3, pp 291-295, issn 0924-8579, 5 p.Article

Antibiotic resistance: Where do ketolides fit?WHITE, Roger L.Pharmacotherapy. 2002, Vol 22, Num 1, pp 18-29, issn 0277-0008, 2Conference Paper

Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase ProducersCRANDON, Jared L; NICOLAU, David P.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 7, pp 3299-3306, issn 0066-4804, 8 p.Article